분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-08-19 18:57:50 , Hit : 269
 Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

https://www.empr.com/news/lenvima-lenvatinib-hepatocellular-carcinoma-approved-hcc-liver-cancer/article/789154/


MPR >
News >
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

  


Da Hee Han, PharmD


August 16, 2018

The Food and Drug Administration (FDA) has approved Lenvima (lenvatinib; Eisai) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC. Study patients received Lenvima based on actual body weight or sorafenib until radiological disease progression or unacceptable toxicity.

Lenvima proved noninferior but not statistically superior to sorafenib for overall survival (hazard ratio [HR] 0.92, 95% CI, 0.79, 1.06). In the Lenvima arm, median overall survival was 13.6 months compared with 12.3 months in the sorafenib arm. Also, a statistically significant improvement in progression-free survival (PFS) was seen with Lenvima vs sorafenib (7.3 months vs 3.6 months; HR 0.64, 95% CI, 0.55, 0.75; P <.001) according to modified Response Evaluation Criteria in Solid Tumors (RECIST) for HCC. Moreover, the objective response rate was greater in the Lenvima arm compared with sorafenib (41% vs 12% per mRECIST; 19% vs 7% per RECIST 1.1).  



Related Articles
Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma
Positive Top-Line Results for Ramucirumab in HCC Announced
BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hep B


Lenvima, a kinase inhibitor, is already indicated in combination with everolimus to treat advanced renal cell carcinoma, following one prior anti-angiogenic therapy; and to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

It is supplied as 4mg and 10mg strength capsules.

For more information call (877) 873-4724 or visit Lenvima.com.







7   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 294
6   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 286
5   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 283
  Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 269
3   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 264
2   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 259
1   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 245

[이전 10개] [1]..[61][62][63] 64
 

Copyright 1999-2021 Zeroboard / skin by ROBIN